FDA-approved drug screening in patient-derived organoids demonstrates potential of drug repurposing for rare cystic fibrosis genotypes
Journal of Cystic Fibrosis · 2023-05 · 22 (3) · 548-559
DOI: 10.1016/j.jcf.2023.03.004 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cystic Fibrosis, 2023-05. Verfasst von E de Poel und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Respiratory Medicine, Wilhelmina Children's Hospital, University Medical Center, Utrecht University, Utrecht, EA 3584, the Ne…. Hauptthemen laut MEDLINE: Cystic Fibrosis, Phosphodiesterase 4 Inhibitors. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: ZonMw, Nederlandse Cystic Fibrosis Stichting.
Abstract (Originalsprache)
BACKGROUND: Preclinical cell-based assays that recapitulate human disease play an important role in drug repurposing. We previously developed a functional forskolin induced swelling (FIS) assay using patient-derived intestinal organoids (PDIOs), allowing functional characterization of CFTR, the gene mutated in people with cystic fibrosis (pwCF). CFTR function-increasing pharmacotherapies have revolutionized treatment for approximately 85% of people with CF who carry the most prevalent F508del-CFTR mutation, but a large unmet need remains to identify new treatments for all pwCF. METHODS: We used 76 PDIOs not homozygous for F508del-CFTR to test the efficacy of 1400 FDA-approved drugs on improving CFTR function, as measured in FIS assays. The most promising hits were verified in a secondary FIS screen. Based on the results of this secondary screen, we further investigated CFTR elevating function of PDE4 inhibitors and currently existing CFTR modulators. RESULTS: In the primary screen, 30 hits were characterized that elevated CFTR function. In the secondary validation screen, 19 hits were confirmed and categorized in three main drug families: CFTR modulators, PDE4 inhibitors and tyrosine kinase inhibitors. We show that PDE4 inhibitors are potent CFTR function inducers in PDIOs where residual CFTR function is either present, or created by additional compound exposure. Additionally, upon CFTR modulator treatment we show rescue of CF genotypes that are currently not eligible for this therapy. CONCLUSION: This study exemplifies the feasibility of high-throughput compound screening using PDIOs. We show the potential of repurposing drugs for pwCF carrying non-F508del genotypes that are currently not eligible for therapies. ONE-SENTENCE SUMMARY: We screened 1400 FDA-approved drugs in CF patient-derived intestinal organoids using the previously established functional FIS assay, and show the potential of repurposing PDE4 inhibitors and CFTR modulators for rare CF genotypes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatric Respiratory Medicine, Wilhelmina Children's Hospital, University Medical Center, Utrecht University, Utrecht, EA 3584, the Netherlands; Regenerative Medicine Utrecht, University Medical Center, U…
- Department of Pediatric Respiratory Medicine, Wilhelmina Children's Hospital, University Medical Center, Utrecht University, Utrecht, EA 3584, the Netherlands.
- Department of Pulmonology, Erasmus MC, University Medical Center, Rotterdam, GD 3015, the Netherlands.
- Haga Teaching Hospital, The Hague, CH 2545, the Netherlands.
- Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, XZ 6525, the Netherlands.
- Maastricht University Medical Center, Maastricht, HX 6229, the Netherlands.
Förderung
- ZonMw
- Nederlandse Cystic Fibrosis Stichting
Zitieren
APA
de Poel, E., Spelier, S., Hagemeijer, M. C., van Mourik, P., Suen, S. W. F., Vonk, A. M., Brunsveld, J. E., Ithakisiou, G. N., Kruisselbrink, E., Oppelaar, H., Berkers, G., de Winter de Groot, K. M., Heida-Michel, S., Jans, S. R., van Panhuis, H., Bakker, M., van der Meer, R., Roukema, J., Dompeling, E., …, & Beekman, J. M. (2023). FDA-approved drug screening in patient-derived organoids demonstrates potential of drug repurposing for rare cystic fibrosis genotypes. Journal of Cystic Fibrosis, 22(3), 548-559. https://doi.org/10.1016/j.jcf.2023.03.004
Vancouver
de Poel E, Spelier S, Hagemeijer MC, van Mourik P, Suen SWF, Vonk AM, et al. FDA-approved drug screening in patient-derived organoids demonstrates potential of drug repurposing for rare cystic fibrosis genotypes. Journal of Cystic Fibrosis. 2023;22(3):548-559. doi:10.1016/j.jcf.2023.03.004
BibTeX
@article{dePoel2023,
author = {de Poel, E and Spelier, S and Hagemeijer, M C and van Mourik, P and Suen, S W F and Vonk, A M and Brunsveld, J E and Ithakisiou, G N and Kruisselbrink, E and Oppelaar, H and Berkers, G and de Winter de Groot, K M and Heida-Michel, S and Jans, S R and van Panhuis, H and Bakker, M and van der Meer, R and Roukema, J and Dompeling, E and Weersink, E J M and Koppelman, G H and Blaazer, A R and Muijlwijk-Koezen, J E and van der Ent, C K and Beekman, J M},
title = {FDA-approved drug screening in patient-derived organoids demonstrates potential of drug repurposing for rare cystic fibrosis genotypes},
journal = {Journal of Cystic Fibrosis},
year = {2023},
volume = {22},
number = {3},
pages = {548--559},
doi = {10.1016/j.jcf.2023.03.004}
}
EUVIMED